UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
OBJECTIVES: In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term m...
主要な著者: | Palace, J, Bregenzer, T, Tremlett, H, Oger, J, Zhu, F, Boggild, M, Duddy, M, Dobson, C |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
BMJ Group
2014
|
類似資料
-
UK multiple sclerosis risksharing scheme: A new natural history dataset and an improved Markov model
著者:: Palace, J, 等
出版事項: (2014) -
Modelling natural history for the UK multiple sclerosis risk-sharing scheme
著者:: Palace, J, 等
出版事項: (2013) -
Improving the model for the uk ms disease modifying treatment risk sharing scheme analysis: a new natural history dataset.
著者:: Palace, J, 等
出版事項: (2013) -
UK multiple sclerosis risksharing scheme: A new natural history dataset and an improved Markov model (BMJ Open (2014) 4, (e004073))
著者:: Palace, J, 等
出版事項: (2014) -
THE UK MS RISK-SHARING SCHEME: RESULTS FOR YEARS 4 AND 6
著者:: Duddy, M, 等
出版事項: (2014)